L-Nutra Secures $83.5M Series D, Fuels Global Longevity & Medical Nutrition Expansion
January 24, 2026, 3:54 pm
Location: United Arab Emirates, Abu Dhabi Emirate, Abu Dhabi
Employees: 501-1000
Founded date: 2002
L-Nutra, a Los Angeles nutri-technology leader, closed its Series D funding, securing an additional $36.5 million. This brings the total Series D raise to $83.5 million. Mubadala Investment Company spearheaded the latest round. The capital propels L-Nutra's global expansion. A new joint venture in Abu Dhabi is key. It targets the Middle East and North Africa. This partnership delivers advanced medical nutrition therapies. Longevity programs will also expand. L-Nutra focuses on science-driven nutrition. It aims to enhance human healthspan. Its programs address chronic disease remission. This strategic move establishes Abu Dhabi as a hub. It strengthens the UAE's life sciences ecosystem. The investment underscores a growing market for preventive health. It highlights the future of personalized nutrition. This funding accelerates L-Nutra's mission. It brings innovative health solutions worldwide. The company leverages extensive research and patents.
L-Nutra, a trailblazer in nutri-technology, has finalized its Series D funding. The Los Angeles-based company announced an additional $36.5 million investment. This latest capital injection brings L-Nutra’s total Series D proceeds to $83.5 million. Mubadala Investment Company led the funding round. This significant financial boost empowers L-Nutra's ambitious global strategy. It targets widespread expansion and enhanced development efforts.
The investment fuels L-Nutra's core mission. It aims to advance "nutrition as medicine" programs. It also scales its longevity-focused initiatives. These programs are designed to extend human healthspan. They seek to drive remission in chronic diseases. This funding reinforces L-Nutra's position as a leader. It stands at the forefront of science-driven nutrition.
A cornerstone of this expansion is a new joint venture. This partnership forms in Abu Dhabi. L-Nutra collaborates with Mubadala Investment Company on this venture. The joint entity will produce and distribute L-Nutra’s scientific medical nutrition therapies. It will also deliver its longevity nutrition offerings. This strategic reach covers the Middle East and North Africa (MENA) region. The collaboration has already begun local efforts. It delivers healthier nutrition and education programs. Seven schools in Abu Dhabi currently benefit.
L-Nutra's platform centers on clinically validated nutrition programs. These support healthy aging processes. They also aim to improve outcomes in chronic health conditions. The company markets some programs under its Prolon brand. Other offerings include specialized medical nutrition therapies. These initiatives stem from decades of dedicated research and development.
The company's scientific rigor is well-established. It boasts partnerships with 18 global university research centers. L-Nutra's work is supported by 47 clinical trials. An impressive 137 granted patents underpin its proprietary formulations. This extensive portfolio protects its unique approaches. It safeguards its advanced nutritional discoveries. It underscores L-Nutra's scientific leadership in the field.
Mubadala's investment signals a broader strategic vision. Abu Dhabi aims to become a regional hub. This hub focuses on longevity science. It emphasizes preventive health. It champions advanced nutrition technologies. This initiative aligns with the UAE's expanding life sciences ecosystem. The partnership facilitates economic diversification. It supports the nation's knowledge-based economy. This investment is more than financial. It is a commitment to public health innovation.
The demand for preventive health solutions is growing. Global populations face rising rates of chronic conditions. Interest in extending healthy life years is surging. L-Nutra's offerings meet this critical market need. Its science-backed approach differentiates it. The company reformulates food. It transforms it into powerful, therapeutic nutrition programs. These programs offer new pathways for health improvement. They provide alternatives to traditional pharmacological interventions.
L-Nutra’s focus on nutrition for longevity is particularly timely. An aging global demographic creates new healthcare challenges. Solutions that proactively manage health become vital. Programs like Prolon provide structured nutritional interventions. They aim to optimize cellular function. They support metabolic health. They contribute to sustained vitality.
The "nutrition as medicine" paradigm is gaining traction. Healthcare systems seek sustainable, effective treatments. L-Nutra's therapies offer a unique proposition. They target underlying mechanisms of disease. They leverage the body's natural healing capabilities. This approach can lead to improved health outcomes. It potentially reduces healthcare burdens.
The joint venture in the MENA region holds significant promise. The region presents a vast, underserved market. It has a growing awareness of health and wellness. L-Nutra's expansion will bring advanced nutritional science to new populations. This move will foster regional health education. It will improve access to cutting-edge therapies. It establishes a strong foothold for future growth.
Existing investors include Brentwood Associates. Moderna CEO Stéphane Bancel also backs the company. 618 Ventures completes this robust investor base. Their continued support highlights L-Nutra's potential. It validates its innovative business model. This collective investment empowers L-Nutra. It will accelerate its research. It will expand its commercial reach. The company is poised for significant impact. It aims to transform health worldwide.
L-Nutra, a trailblazer in nutri-technology, has finalized its Series D funding. The Los Angeles-based company announced an additional $36.5 million investment. This latest capital injection brings L-Nutra’s total Series D proceeds to $83.5 million. Mubadala Investment Company led the funding round. This significant financial boost empowers L-Nutra's ambitious global strategy. It targets widespread expansion and enhanced development efforts.
The investment fuels L-Nutra's core mission. It aims to advance "nutrition as medicine" programs. It also scales its longevity-focused initiatives. These programs are designed to extend human healthspan. They seek to drive remission in chronic diseases. This funding reinforces L-Nutra's position as a leader. It stands at the forefront of science-driven nutrition.
A cornerstone of this expansion is a new joint venture. This partnership forms in Abu Dhabi. L-Nutra collaborates with Mubadala Investment Company on this venture. The joint entity will produce and distribute L-Nutra’s scientific medical nutrition therapies. It will also deliver its longevity nutrition offerings. This strategic reach covers the Middle East and North Africa (MENA) region. The collaboration has already begun local efforts. It delivers healthier nutrition and education programs. Seven schools in Abu Dhabi currently benefit.
L-Nutra's platform centers on clinically validated nutrition programs. These support healthy aging processes. They also aim to improve outcomes in chronic health conditions. The company markets some programs under its Prolon brand. Other offerings include specialized medical nutrition therapies. These initiatives stem from decades of dedicated research and development.
The company's scientific rigor is well-established. It boasts partnerships with 18 global university research centers. L-Nutra's work is supported by 47 clinical trials. An impressive 137 granted patents underpin its proprietary formulations. This extensive portfolio protects its unique approaches. It safeguards its advanced nutritional discoveries. It underscores L-Nutra's scientific leadership in the field.
Mubadala's investment signals a broader strategic vision. Abu Dhabi aims to become a regional hub. This hub focuses on longevity science. It emphasizes preventive health. It champions advanced nutrition technologies. This initiative aligns with the UAE's expanding life sciences ecosystem. The partnership facilitates economic diversification. It supports the nation's knowledge-based economy. This investment is more than financial. It is a commitment to public health innovation.
The demand for preventive health solutions is growing. Global populations face rising rates of chronic conditions. Interest in extending healthy life years is surging. L-Nutra's offerings meet this critical market need. Its science-backed approach differentiates it. The company reformulates food. It transforms it into powerful, therapeutic nutrition programs. These programs offer new pathways for health improvement. They provide alternatives to traditional pharmacological interventions.
L-Nutra’s focus on nutrition for longevity is particularly timely. An aging global demographic creates new healthcare challenges. Solutions that proactively manage health become vital. Programs like Prolon provide structured nutritional interventions. They aim to optimize cellular function. They support metabolic health. They contribute to sustained vitality.
The "nutrition as medicine" paradigm is gaining traction. Healthcare systems seek sustainable, effective treatments. L-Nutra's therapies offer a unique proposition. They target underlying mechanisms of disease. They leverage the body's natural healing capabilities. This approach can lead to improved health outcomes. It potentially reduces healthcare burdens.
The joint venture in the MENA region holds significant promise. The region presents a vast, underserved market. It has a growing awareness of health and wellness. L-Nutra's expansion will bring advanced nutritional science to new populations. This move will foster regional health education. It will improve access to cutting-edge therapies. It establishes a strong foothold for future growth.
Existing investors include Brentwood Associates. Moderna CEO Stéphane Bancel also backs the company. 618 Ventures completes this robust investor base. Their continued support highlights L-Nutra's potential. It validates its innovative business model. This collective investment empowers L-Nutra. It will accelerate its research. It will expand its commercial reach. The company is poised for significant impact. It aims to transform health worldwide.